题名 | A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer. |
作者 | Zhang Y1, Gao C, Qu W, Gao Y, Zhu S, Zhang S, He W, Yu Y. |
杂志 | Cancer Invest. 2015 Jul;33(6):241-5 |
链接 | Cancer Invest. 2015 Jul;33(6):241-5 |
欢迎光临 科研速递论坛 (http://www.expaper.cn/) | Powered by Discuz! X2.5 |